View in EDS HTML Full Text PDF Full Text

The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment

Saved in:
Bibliographic Details
Title: The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment
Authors: Herold, Stephanie1 (AUTHOR) stephanie.herold@unimedizin-mainz.de, Schmidt, Christian2 (AUTHOR), Visco, Carlo3 (AUTHOR), Tilch, Marie-Kristin1 (AUTHOR), Ohler, Anke1 (AUTHOR), Unterhalt, Michael2 (AUTHOR), Hoster, Eva4 (AUTHOR), Hoenig, Elisabeth5 (AUTHOR), Singer, Susanne6 (AUTHOR), Tucci, Alessandra7 (AUTHOR), Pott, Christiane8 (AUTHOR), Ladetto, Marco9 (AUTHOR), Hess, Georg1 (AUTHOR), Dreyling, Martin2 (AUTHOR)
Source: BMC Cancer. 8/25/2025, Vol. 25 Issue 1, p1-9. 9p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14712407
DOI:10.1186/s12885-025-14803-8